Liability Related to the Sale of Future Royalties (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Nov. 30, 2022	Dec. 31, 2023	Dec. 31, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-cash interest expense on liability related to the sale of future royalties		$ 5,367	$ 2,849
Royalty Pharma Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment	$ 250,000
Milestone payment receivable	160,000
Milestone payment receivable upon achievement of enrollment in phase 3 clinical trial	50,000
Milestone payment receivable upon FDA approval	50,000
Milestone payment receivable upon receipt of royalty payments	60,000
Royalty payment threshold	70,000
Liability related to the sale of future royalties		250,000
Non-cash interest expense on liability related to the sale of future royalties		$ 5,400	$ 2,800
Royalty Pharma Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Initial transaction price	$ 410,000